ORIC Pharmaceuticals Receives $53,000,000 Series B Round

  • Feed Type
  • Date
    12/3/2015
  • Company Name
    ORIC Pharmaceuticals
  • Mailing Address
    240 E. Grand Ave. 2nd Floor South San Francisco, CA 94080 USA
  • Company Description
    ORIC Pharmaceuticals is a privately-held company dedicated to discovering and developing novel therapies for treatment-resistant cancers. While recent advances with targeted therapeutics have extended prognoses in many disease settings, cancers often develop resistance to current drugs.
  • Website
    http://www.oricpharma.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $53,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    The funds will be used to support advancement of the company’s first drug candidate into initial clinical trials and to further develop the company’s pipeline.
  • M&A Terms
  • Venture Investor
    The Column Group
  • Venture Investor
    Topspin Partners
  • Venture Investor
    OrbiMed
  • Venture Investor
    EcoR1 Capital Management
  • Venture Investor
    Foresite Capital
  • Venture Investor
    Undisclosed

Trending on Xconomy